Press Releases
Page 6 • 12 itemsAccess critical pharma & biotech press releases. Stay ahead on drug approvals, clinical trials, M&A, and regulatory updates impacting global markets.
Crinetics Pharmaceuticals Receives EU Approval for PALSONIFY (Paltusotine), First Oral Daily Acromegaly Treatment
Crinetics Pharmaceuticals announces European Commission approval of PALSONIFY (paltusotine), the first once-daily oral therapy for acromegaly in adults.
Boston Scientific Corporation Faces Securities Class Action Lawsuit with May 4 Deadline for Investors
Boston Scientific investors have until May 4, 2026 to join securities class action lawsuit. Rosen Law Firm encourages shareholders to secure legal counsel.
Brii Bio's Elebsiran Shows Durable Hepatitis B Control in APASL 2026 Cross-Study Analysis
Brii Bio's elebsiran combined with pegylated interferon demonstrates sustained HBsAg loss and favorable off-treatment outcomes in hepatitis B patients.
Aetna Standardizes 88% of Prior Authorization Volume, Exceeds Industry Commitments for Healthcare Access
Aetna announces 88% prior authorization standardization, surpassing industry goals while maintaining fewest medical service requirements among national health plans.
Guerbet's Lipiodol Ultra Fluid Achieves EU Regulatory Milestone for Vascular Embolization Procedures
Guerbet announces positive EU regulatory outcome for Lipiodol Ultra Fluid in vascular embolization, expanding interventional radiology applications.
RNA Therapy Clinical Trials Market Reaches $3.4 Billion as Personalized Medicine Drives Growth Through 2035
RNA therapy clinical trials market hits $3.4B driven by delivery advances, rare disease funding, and personalized medicine growth through 2035.
Oncotelic Therapeutics Updates Partnership Strategy for Cancer Drug Development Pipeline
Oncotelic Therapeutics provides corporate update on strategic partnerships to advance clinical-stage cancer treatments and expand market reach.
CLINUVEL Receives EMA Approval for SCENESSE Phase III Vitiligo Trial Starting 2026
CLINUVEL gets final EMA scientific advice for pivotal Phase III vitiligo study comparing SCENESSE with NB-UVB therapy, set to begin second half 2026.
RenovoRx TAMP Therapy Platform Data Accepted for 2026 ASCO Presentation - Phase III TIGeR-PaC Trial Results
RenovoRx announces ASCO acceptance of pharmacokinetic data from Phase III TIGeR-PaC trial testing TAMP therapy platform for pancreatic cancer treatment.
Genomics Services Market to Reach $24 Billion by 2033 as Precision Medicine Adoption Accelerates
The global genomics services market is projected to grow at 11.2% CAGR through 2033, driven by precision medicine advances and digital health initiatives.
Accenture Invests in Iridius to Accelerate AI Compliance Solutions for Life Sciences Companies
Accenture Ventures invests in Iridius to help pharmaceutical companies adopt compliant AI solutions while maintaining regulatory standards and auditability.
Pharmaceutical Company Reports Continued Growth Momentum in Q1 2026 Sales Results
Major pharmaceutical company announces sustained growth in first quarter 2026 sales, maintaining positive momentum from previous periods with investor call scheduled.